The positive irEC data provides a major pipeline catalyst that could attract partnership interest from ICI franchise holders. Watch for partnership announcements and funding updates for the allo-HCT Phase 2 study as key near-term catalysts.
Price Chart
Executive Summary
Seres Therapeutics announced positive top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC). 80% of participants achieved the primary endpoint of immunosuppressive-free clinical response at Day 15, with a favorable safety profile. The company is engaging with potential partners for SER-155 development in irEC and seeks funding to advance the SER-155 Phase 2 study in allo-HCT and its broader pipeline, with cash runway projected into Q1 2027.
Key Facts
- 80% (12/15) of participants achieved immunosuppressive-free clinical response at Day 15 (primary endpoint) for SER-155 in irEC
- 33% (5/15) achieved immunosuppressive-free complete clinical remission at Day 15
- No serious adverse events related to SER-155 were reported; consistent with prior Phase 1b safety data
- Cash runway projected into Q1 2027 with ~$29.8M cash at March 31, 2026
- Nestlé Health Science to buy out future VOWST milestones for $25M, paid in two equal installments in July and October 2026
- Company engaging with potential partners for SER-155 in irEC, including companies with ICI franchises
Financial Impact
Positive clinical data for SER-155 in a large and growing market (irEC) could significantly enhance partnership prospects; $25M near-term cash infusion from VOWST milestone buyout provides extended runway
Risk Factors
- Company needs additional funding to advance SER-155 Phase 2 in allo-HCT and broader pipeline; partnership or capital raise required
- IST data is from a small, open-label study (n=15); larger controlled trials needed to confirm findings
- Company has history of going concern risk and Nasdaq listing compliance issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-298005 |
| Document: d130829d8k.htm | 0001193125-26-298005 |
| Document: d130829dex991.htm | 0001193125-26-298005 |
| Document: 0001193125-26-298005-index-headers.html | 0001193125-26-298005 |
| Document: 0001193125-26-298005-index.html | 0001193125-26-298005 |
| Document: 0001193125-26-298005.txt | 0001193125-26-298005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 9w ago | EFFECT | $4.66 $4.02 | ▲ +13.73% | ▲ +15.05% | $1.98 (+57.51%) |
Aug 5, 2026 11w ago | 8-K | $5.01 $5.54 | ▲ +10.69% | ▲ +11.29% | $1.98 (−60.44%) |
Jul 8, 2026 15w ago | 8-K | $7.14 $5.01 | ▼ −29.90% | ▼ −33.17% | $1.98 (−72.27%) |
Jun 5, 2026 20w ago | 8-K | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.98 (−70.14%) |
Jun 5, 2026 20w ago | Press Release | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.98 (−70.14%) |
May 19, 2026 22w ago | Insider Cluster | $7.66 $6.61 | ▼ −13.71% | ▼ −14.45% | $1.98 (−74.15%) |
May 5, 2026 24w ago | 8-K | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.98 (+73.60%) |
May 5, 2026 24w ago | Press Release | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.98 (+73.60%) |
May 4, 2026 25w ago | Press Release | $7.69 $7.64 | ▼ −0.65% | ▼ −6.30% | $1.98 (−74.25%) |
Mar 12, 2026 32w ago | 8-K | $9.05 $8.32 | ▼ −8.07% | ▼ −10.04% | $1.98 (−78.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers